GFAP, a marker of astroglial activation, is valuable for identifying neuroinflammatory processes, while NfL is highly sensitive to neurodegeneration and shows promise in distinguishing AD from non-AD dementias like frontotemporal dementia and CBS [14–16]. This evidence concerns the gene GFAP and Alzheimer disease.